Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

U.S. CDC backs COVID boosters for children 5 to 11

Published 05/19/2022, 09:32 AM
Updated 05/19/2022, 10:26 PM
© Reuters. FILE PHOTO: A child reacts while receiving a dose of the Pfizer-BioNTech coronavirus disease (COVID-19) vaccine at Smoketown Family Wellness Center in Louisville, Kentucky, U.S., November 8, 2021. REUTERS/Jon Cherry/

By Manas Mishra and Michael Erman

(Reuters) -The U.S. Centers for Disease Control and Prevention (CDC) on Thursday recommended the COVID-19 vaccine booster for children ages 5 to 11 after an advisory panel voted to back them, at least five months after completing their primary vaccination course.

CDC Director Rochelle Walensky said in a statement that she "endorsed" the vote by the Advisory Committee on Immunization Practices "to expand eligibility for COVID-19 vaccine booster doses. Children 5 through 11 should receive a booster dose at least 5 months after their primary series."

"With over 18 million doses administered in this age group, we know that these vaccines are safe, and we must continue to increase the number of children who are protected," Walensky added.

The advisers considered data from the CDC that showed protection from the initial two shots starts to wane over time, and that boosters in older age groups improved efficacy against severe COVID and hospitalizations.

The Food and Drug Administration authorized booster doses of the Pfizer/BioNTech vaccine for the age group on Tuesday as COVID cases are on the rise again in the United States.

The U.S. government has been pushing for eligible Americans to get boosted, but fewer than half of those who are fully vaccinated have rolled up their sleeves for an additional shot.

Pfizer (NYSE:PFE) said at the meeting that data showed a third dose of its vaccine generated a strong immune response against the Omicron variant in healthy children ages 5-11 years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The CDC also presented safety data showing that the incidence of heart inflammation after vaccination in the age group was significantly lower than in adolescents and young adults.

Just over 29% of U.S. children ages 5-11 are considered fully vaccinated with two doses of the Pfizer/BioNTech shot. The vaccine is not yet authorized for children younger than 5.

The vaccine committee voted 11 to 1 to recommend the additional shots, with one doctor abstaining.

Dr. Helen Keipp Talbot, a professor at Vanderbilt University, was the lone committee member to vote against recommending the boosters, arguing that the focus should be on increasing the vaccination rate in the age group.

"Boosters are great once we've gotten everyone their first round," she said.

Companies are already looking into the possible need for redesigned COVID-19 vaccines for the fall to target new variants of concern.

CDC scientist Dr. Amanda Cohn said redesigned vaccines may not be available for children right away because the pediatric shots are a different formulation than what would be given to adults.

Latest comments

Uh oh CDC and COVID and children mentioned together. This will surely trigger the extreme science denying right wing snowflakes.
Horrible. The pandemic of the boosted.
Hey Walensky, point to anything in your own public data that shows this group includes “those most vulnerable.”
They need to run another study to verify the data......at St Jude's. ;-)
Nope
Any parent that injected a 5-11 year old with this poison, deserves everything that is coming.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.